$KPTI
Karyopharm Therapeutics Inc.

2023 Q1 Form 10-K Financial Statement

#000095017023003129 Filed on February 17, 2023

View on sec.gov

Income Statement

Concept 2023 Q1 2022 Q4 2022
Revenue $38.70M $33.58M $157.1M
YoY Change -18.82% -73.41% -25.14%
Cost Of Revenue $1.351M $1.868M $5.213M
YoY Change -5.26% 151.75% 53.23%
Gross Profit $37.35M $31.71M $151.9M
YoY Change -19.24% -74.74% -26.43%
Gross Profit Margin 96.51% 94.44% 96.68%
Selling, General & Admin $35.91M $34.65M $145.4M
YoY Change -7.38% 0.25% 1.08%
% of Gross Profit 96.14% 109.26% 95.75%
Research & Development $32.34M $30.93M $148.7M
YoY Change -23.12% -29.7% -7.57%
% of Gross Profit 86.59% 97.54% 97.89%
Depreciation & Amortization $290.0K $113.0K $621.0K
YoY Change 63.84% -18.71% -22.38%
% of Gross Profit 0.78% 0.36% 0.41%
Operating Expenses $69.60M $65.58M $299.3M
YoY Change -15.39% -16.53% -2.86%
Operating Profit -$30.90M -$33.87M -$142.2M
YoY Change -10.66% -172.12% 44.7%
Interest Expense $5.758M -$4.551M $25.00M
YoY Change -13.85% -42.28% -4.03%
% of Operating Profit
Other Income/Expense, Net -$3.173M -$13.00K -$22.72M
YoY Change -52.52% -97.28% -11.07%
Pretax Income -$34.07M -$38.43M -$164.9M
YoY Change -17.44% -199.57% 33.19%
Income Tax $54.00K $73.00K $400.0K
% Of Pretax Income
Net Earnings -$34.13M -$38.51M -$165.3M
YoY Change -17.57% -199.45% 33.2%
Net Earnings / Revenue -88.19% -114.67% -105.23%
Basic Earnings Per Share -$0.30 -$2.02
Diluted Earnings Per Share -$0.30 -$0.43 -$2.02
COMMON SHARES
Basic Shares Outstanding 113.3M 81.87M
Diluted Shares Outstanding 113.5M 81.87M

Balance Sheet

Concept 2023 Q1 2022 Q4 2022
SHORT-TERM ASSETS
Cash & Short-Term Investments $260.4M $278.0M $278.0M
YoY Change 26.82% 21.59% 21.59%
Cash & Equivalents $84.06M $135.2M $135.2M
Short-Term Investments $176.3M $142.8M $142.8M
Other Short-Term Assets $19.13M $20.89M $20.89M
YoY Change -34.34% 1266.82% 2.44%
Inventory $3.827M $4.224M $4.224M
Prepaid Expenses
Receivables $35.20M $47.09M $47.09M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $318.5M $350.2M $350.2M
YoY Change 15.19% 27.05% 27.05%
LONG-TERM ASSETS
Property, Plant & Equipment $849.0K $1.139M $7.377M
YoY Change -45.01% -30.63% -22.81%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $634.0K $633.0K $633.0K
YoY Change -92.49% -96.86% -96.86%
Total Long-Term Assets $7.259M $8.010M $8.010M
YoY Change -58.52% -73.03% -73.03%
TOTAL ASSETS
Total Short-Term Assets $318.5M $350.2M $350.2M
Total Long-Term Assets $7.259M $8.010M $8.010M
Total Assets $325.8M $358.2M $358.2M
YoY Change 10.8% 17.32% 17.32%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $9.045M $2.773M $2.773M
YoY Change 162.94% 72.99% 72.99%
Accrued Expenses $47.03M $58.42M $61.29M
YoY Change -19.43% -15.49% -14.21%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $61.56M $65.91M $65.91M
YoY Change -7.21% -10.59% -10.59%
LONG-TERM LIABILITIES
Long-Term Debt $303.0M $302.8M $302.8M
YoY Change 0.18% 0.18% 0.18%
Other Long-Term Liabilities $1.085M $6.097M $6.097M
YoY Change -86.91% -32.02% -32.02%
Total Long-Term Liabilities $1.085M $308.9M $308.9M
YoY Change -99.65% -0.75% -0.75%
TOTAL LIABILITIES
Total Short-Term Liabilities $61.56M $65.91M $65.91M
Total Long-Term Liabilities $1.085M $308.9M $308.9M
Total Liabilities $371.0M $374.8M $374.8M
YoY Change -1.63% -2.64% -2.64%
SHAREHOLDERS EQUITY
Retained Earnings -$1.378B -$1.300B
YoY Change 12.95% 10.3%
Common Stock $1.333B $1.328B
YoY Change 17.28% 20.85%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$45.17M -$16.66M -$16.66M
YoY Change
Total Liabilities & Shareholders Equity $325.8M $358.2M $358.2M
YoY Change 10.8% 17.32% 17.32%

Cashflow Statement

Concept 2023 Q1 2022 Q4 2022
OPERATING ACTIVITIES
Net Income -$34.13M -$38.51M -$165.3M
YoY Change -17.57% -199.45% 33.2%
Depreciation, Depletion And Amortization $290.0K $113.0K $621.0K
YoY Change 63.84% -18.71% -22.38%
Cash From Operating Activities -$18.91M -$26.84M -$149.6M
YoY Change -68.06% -205.37% 39.62%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $0.00 $118.0K
YoY Change -100.0% -100.0% -44.34%
Acquisitions
YoY Change
Other Investing Activities -$32.39M -$65.30M -$104.1M
YoY Change 132.07% -310.8% -173.31%
Cash From Investing Activities -$32.39M -$65.30M -$104.3M
YoY Change 130.77% -312.21% -173.5%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 155.8M 193.7M
YoY Change -100.0% 17293.19% 163.06%
NET CHANGE
Cash From Operating Activities -18.91M -26.84M -149.6M
Cash From Investing Activities -32.39M -65.30M -104.3M
Cash From Financing Activities 0.000 155.8M 193.7M
Net Change In Cash -51.34M 63.70M -60.56M
YoY Change 20.7% 11.48% -155.91%
FREE CASH FLOW
Cash From Operating Activities -$18.91M -$26.84M -$149.6M
Capital Expenditures $0.00 $0.00 $118.0K
Free Cash Flow -$18.91M -$26.84M -$149.7M
YoY Change -68.1% -204.52% 39.45%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021 us-gaap Available For Sale Debt Securities Gross Unrealized Loss
AvailableForSaleDebtSecuritiesGrossUnrealizedLoss
9000
CY2021Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
38156000
CY2022 dei Amendment Flag
AmendmentFlag
false
CY2022 dei Entity Central Index Key
EntityCentralIndexKey
0001503802
CY2022 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2021Q4 kpti Deferred Tax Assets Deferred Royalty Obligations
DeferredTaxAssetsDeferredRoyaltyObligations
CY2022 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2022 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
CY2022 dei Document Transition Report
DocumentTransitionReport
false
CY2022 dei Entity File Number
EntityFileNumber
001-36167
CY2022 dei Document Type
DocumentType
10-K
CY2022 dei Document Annual Report
DocumentAnnualReport
true
CY2022 dei Entity Registrant Name
EntityRegistrantName
KARYOPHARM THERAPEUTICS INC.
CY2022 dei Document Period End Date
DocumentPeriodEndDate
2022-12-31
CY2022 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1642000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
7915000
CY2022Q4 us-gaap Other Assets
OtherAssets
0
CY2021Q4 us-gaap Other Assets
OtherAssets
19505000
CY2022 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
26-3931704
CY2022 dei Entity Address Address Line1
EntityAddressAddressLine1
85 Wells Avenue, 2nd Floor
CY2022 dei Entity Address City Or Town
EntityAddressCityOrTown
Newton
CY2022 dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
CY2022 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02459
CY2022 dei City Area Code
CityAreaCode
617
CY2022 dei Local Phone Number
LocalPhoneNumber
658-0600
CY2022 dei Security12b Title
Security12bTitle
Common Stock
CY2022 dei Trading Symbol
TradingSymbol
KPTI
CY2022 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2022 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
Yes
CY2022 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2022 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2022 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2022 dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
CY2022 dei Entity Small Business
EntitySmallBusiness
false
CY2022 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2022 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
true
CY2022 dei Entity Shell Company
EntityShellCompany
false
CY2022Q2 dei Entity Public Float
EntityPublicFloat
351300000
CY2023Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
113342130
CY2022 dei Auditor Firm
AuditorFirmId
42
CY2022 dei Auditor Name
AuditorName
Ernst & Young LLP
CY2022 dei Auditor Location
AuditorLocation
Boston, Massachusetts
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
135188000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
190459000
CY2022Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
142779000
CY2021Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
38156000
CY2022Q4 us-gaap Receivables Net Current
ReceivablesNetCurrent
47086000
CY2021Q4 us-gaap Receivables Net Current
ReceivablesNetCurrent
22497000
CY2022Q4 us-gaap Inventory Net
InventoryNet
4224000
CY2021Q4 us-gaap Inventory Net
InventoryNet
4106000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
19821000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
14039000
CY2022Q4 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
1064000
CY2021Q4 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
6349000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
350162000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
275606000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1139000
CY2022Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
633000
CY2021Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
637000
CY2022Q4 us-gaap Assets
Assets
358172000
CY2021Q4 us-gaap Assets
Assets
305305000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2773000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1603000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
6238000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
58415000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
69121000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
2872000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
2316000
CY2022Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
1848000
CY2021Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
678000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
65908000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
73718000
CY2021Q4 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
169293000
CY2022Q4 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
170105000
CY2022Q4 kpti Deferred Royalty Obligation Noncurrent
DeferredRoyaltyObligationNoncurrent
132718000
CY2021Q4 kpti Deferred Royalty Obligation Noncurrent
DeferredRoyaltyObligationNoncurrent
132998000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
6097000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
8969000
CY2022Q4 us-gaap Liabilities
Liabilities
374828000
CY2021Q4 us-gaap Liabilities
Liabilities
384978000
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
113213000
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
113213000
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
75746000
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
75746000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
12000
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
8000
CY2022Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1327909000
CY2021Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1098776000
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-638000
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
191000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1343939000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1178648000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-16656000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
-79673000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
358172000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
305305000
CY2022 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
157074000
CY2021 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
209819000
CY2020 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
108085000
CY2022 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
148662000
CY2021 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
160842000
CY2020 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
150813000
CY2022 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
145401000
CY2021 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
143846000
CY2020 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
126417000
CY2022 us-gaap Operating Expenses
OperatingExpenses
299276000
CY2021 us-gaap Operating Expenses
OperatingExpenses
308090000
CY2020 us-gaap Operating Expenses
OperatingExpenses
279935000
CY2022 us-gaap Operating Income Loss
OperatingIncomeLoss
-142202000
CY2021 us-gaap Operating Income Loss
OperatingIncomeLoss
-98271000
CY2020 us-gaap Operating Income Loss
OperatingIncomeLoss
-171850000
CY2022 us-gaap Investment Income Interest
InvestmentIncomeInterest
2359000
CY2021 us-gaap Investment Income Interest
InvestmentIncomeInterest
582000
CY2020 us-gaap Investment Income Interest
InvestmentIncomeInterest
2820000
CY2022 us-gaap Interest Expense
InterestExpense
24996000
CY2021 us-gaap Interest Expense
InterestExpense
26046000
CY2020 us-gaap Interest Expense
InterestExpense
27140000
CY2022 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-83000
CY2021 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-85000
CY2020 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
206000
CY2022 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-22720000
CY2021 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-25549000
CY2020 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-24114000
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-164922000
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-123820000
CY2020 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-195964000
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
369000
CY2021 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
268000
CY2020 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
309000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-165291000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-124088000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-196273000
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.02
CY2022 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.02
CY2021 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.65
CY2021 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.65
CY2020 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.72
CY2020 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.72
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
81871000
CY2022 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
81871000
CY2021 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
75218000
CY2021 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
75218000
CY2020 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
72044000
CY2020 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
72044000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-165291000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-124088000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-196273000
CY2022 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-341000
CY2021 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-286000
CY2020 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
288000
CY2022 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-488000
CY2021 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-41000
CY2020 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
267000
CY2022 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-166120000
CY2021 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-124415000
CY2020 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-195718000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
49774000
CY2020 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
10307000
CY2020 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
24407000
CY2020 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
161776000
CY2020 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
288000
CY2020 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
267000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-196273000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
50546000
CY2021 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
3745000
CY2021 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
29783000
CY2021 us-gaap Stock Issued During Period Value Purchase Of Assets
StockIssuedDuringPeriodValuePurchaseOfAssets
1355000
CY2021 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
9903000
CY2021 kpti Cumulative Effect Adjustment For Adoption Of New Accounting Guidance
CumulativeEffectAdjustmentForAdoptionOfNewAccountingGuidance
-50590000
CY2021 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-286000
CY2021 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-41000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-124088000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
-79673000
CY2022 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
3977000
CY2022 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
35399000
CY2022 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
189761000
CY2022 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-341000
CY2022 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-488000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-165291000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-16656000
CY2022 us-gaap Profit Loss
ProfitLoss
-165291000
CY2021 us-gaap Profit Loss
ProfitLoss
-124088000
CY2020 us-gaap Profit Loss
ProfitLoss
-196273000
CY2022 us-gaap Share Based Compensation
ShareBasedCompensation
35399000
CY2021 us-gaap Share Based Compensation
ShareBasedCompensation
29783000
CY2020 us-gaap Share Based Compensation
ShareBasedCompensation
24407000
CY2022 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
812000
CY2021 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
780000
CY2020 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
8071000
CY2022 us-gaap Depreciation
Depreciation
621000
CY2021 us-gaap Depreciation
Depreciation
789000
CY2020 us-gaap Depreciation
Depreciation
972000
CY2022 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
825000
CY2021 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-1560000
CY2020 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-1419000
CY2022 us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
0
CY2021 us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
7355000
CY2020 us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
0
CY2022 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
281000
CY2021 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
106000
CY2020 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
186000
CY2022 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
5084000
CY2021 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
9616000
CY2020 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
5019000
CY2022 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
118000
CY2021 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
1462000
CY2020 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
2627000
CY2022 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
5782000
CY2021 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
24759000
CY2020 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1996000
CY2022 kpti Increase Decrease In Operating Lease Right Of Use Asset
IncreaseDecreaseInOperatingLeaseRightOfUseAsset
-1677000
CY2021 kpti Increase Decrease In Operating Lease Right Of Use Asset
IncreaseDecreaseInOperatingLeaseRightOfUseAsset
-1449000
CY2020 kpti Increase Decrease In Operating Lease Right Of Use Asset
IncreaseDecreaseInOperatingLeaseRightOfUseAsset
-1254000
CY2022 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1170000
CY2021 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-2847000
CY2020 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
3465000
CY2022 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-9536000
CY2021 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
16260000
CY2020 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
12161000
CY2022 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
0
CY2021 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-297000
CY2020 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-4236000
CY2022 kpti Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-2316000
CY2021 kpti Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-1917000
CY2020 kpti Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-1646000
CY2022 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-149554000
CY2021 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-107116000
CY2020 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-160234000
CY2022 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
118000
CY2021 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
212000
CY2020 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
145000
CY2022 us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
121878000
CY2021 us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
192780000
CY2020 us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
221037000
CY2022 us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
226016000
CY2021 us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
45228000
CY2020 us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
274577000
CY2022 us-gaap Payments To Acquire In Process Research And Development
PaymentsToAcquireInProcessResearchAndDevelopment
0
CY2021 us-gaap Payments To Acquire In Process Research And Development
PaymentsToAcquireInProcessResearchAndDevelopment
5500000
CY2020 us-gaap Payments To Acquire In Process Research And Development
PaymentsToAcquireInProcessResearchAndDevelopment
0
CY2022 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-104256000
CY2021 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
141840000
CY2020 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-53685000
CY2022 kpti Proceeds From Payments For Common Stock Issuance Net
ProceedsFromPaymentsForCommonStockIssuanceNet
189761000
CY2021 kpti Proceeds From Payments For Common Stock Issuance Net
ProceedsFromPaymentsForCommonStockIssuanceNet
9903000
CY2020 kpti Proceeds From Payments For Common Stock Issuance Net
ProceedsFromPaymentsForCommonStockIssuanceNet
161776000
CY2022 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
3977000
CY2021 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
3745000
CY2020 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
10307000
CY2022 kpti Proceeds From Amended Revenue Interest Agreement
ProceedsFromAmendedRevenueInterestAgreement
0
CY2021 kpti Proceeds From Amended Revenue Interest Agreement
ProceedsFromAmendedRevenueInterestAgreement
60000000
CY2020 kpti Proceeds From Amended Revenue Interest Agreement
ProceedsFromAmendedRevenueInterestAgreement
0
CY2022 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
193738000
CY2021 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
73648000
CY2020 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
172083000
CY2022 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-488000
CY2021 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-48000
CY2020 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
268000
CY2022 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-60560000
CY2021 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
108324000
CY2020 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-41568000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
197445000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
89121000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
130689000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
136885000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
197445000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
89121000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
135188000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
190459000
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
85918000
CY2022Q4 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
1064000
CY2021Q4 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
6349000
CY2020Q4 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
2481000
CY2022Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
633000
CY2021Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
637000
CY2020Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
722000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
136885000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
197445000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
89121000
CY2022 us-gaap Interest Paid Net
InterestPaidNet
5175000
CY2021 us-gaap Interest Paid Net
InterestPaidNet
5175000
CY2020 us-gaap Interest Paid Net
InterestPaidNet
5175000
CY2022 kpti Cash Paid For Amounts Included In Measurement Of Operating Lease Liabilities
CashPaidForAmountsIncludedInMeasurementOfOperatingLeaseLiabilities
3447000
CY2021 kpti Cash Paid For Amounts Included In Measurement Of Operating Lease Liabilities
CashPaidForAmountsIncludedInMeasurementOfOperatingLeaseLiabilities
3277000
CY2020 kpti Cash Paid For Amounts Included In Measurement Of Operating Lease Liabilities
CashPaidForAmountsIncludedInMeasurementOfOperatingLeaseLiabilities
3200000
CY2022 us-gaap Payments For Royalties
PaymentsForRoyalties
29273000
CY2021 us-gaap Payments For Royalties
PaymentsForRoyalties
10361000
CY2020 us-gaap Payments For Royalties
PaymentsForRoyalties
6014000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1300000000
CY2022 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2022 us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Use of Estimates</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On an ongoing basis, we evaluate our estimates, including estimates related to our net product revenue, license and other revenue, clinical trial accruals, stock-based compensation expense, interest expense on our deferred royalty obligation, our embedded derivative liability, valuation allowances, and other reported amounts of expenses during the reported period. We base our estimates on historical experience and other market-specific or relevant assumptions that we believe to be reasonable under the circumstances. Although we regularly assess these estimates, actual results could differ from those estimates. Changes in estimates are recorded in the period in which they become known.</span></p>
CY2022Q4 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
0
CY2021Q4 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
0
CY2022 us-gaap Allowance For Doubtful Accounts Receivable Write Offs
AllowanceForDoubtfulAccountsReceivableWriteOffs
0
CY2022Q4 kpti Available For Sale Securities In Unrealized Loss Positions Qualitative Disclosure Number Of Positions Less Than One Years
AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsLessThanOneYears
60
CY2020Q4 kpti Revenue Recognition Discounts And Charge Backs
RevenueRecognitionDiscountsAndChargeBacks
2079000
CY2020 kpti Revenue Recognition Payments For Fees Rebates And Other Incentives Current Year
RevenueRecognitionPaymentsForFeesRebatesAndOtherIncentivesCurrentYear
-3889000
CY2020 kpti Revenue Recognition Credits For Discounts Charge Backs Fees Rebates Other Incentives And Sales Returns Current Year
RevenueRecognitionCreditsForDiscountsChargeBacksFeesRebatesOtherIncentivesAndSalesReturnsCurrentYear
-12566000
CY2019Q4 kpti Revenue Recognition Discounts And Charge Backs
RevenueRecognitionDiscountsAndChargeBacks
1002000
CY2019Q4 kpti Revenue Recognition Fees Rebates And Other Incentives
RevenueRecognitionFeesRebatesAndOtherIncentives
1819000
CY2019Q4 kpti Revenue Recognition Sales Return
RevenueRecognitionSalesReturn
234000
CY2019Q4 kpti Revenue Recognition Discounts Charge Backs Fees Rebates Other Incentives And Sales Returns
RevenueRecognitionDiscountsChargeBacksFeesRebatesOtherIncentivesAndSalesReturns
3055000
CY2020 kpti Revenue Recognition Provision For Discounts And Charge Backs
RevenueRecognitionProvisionForDiscountsAndChargeBacks
9754000
CY2020 kpti Revenue Recognition Provision For Fees Rebates And Other Incentives
RevenueRecognitionProvisionForFeesRebatesAndOtherIncentives
4263000
CY2020 kpti Revenue Recognition Sale Returns Reserve For Sale Returns
RevenueRecognitionSaleReturnsReserveForSaleReturns
435000
CY2020 kpti Revenue Recognition Provision For Discounts Charge Backs Fees Rebates Other Incentives And Sales Returns
RevenueRecognitionProvisionForDiscountsChargeBacksFeesRebatesOtherIncentivesAndSalesReturns
14452000
CY2020 kpti Revenue Recognition Payments For Chargebacks Current Year
RevenueRecognitionPaymentsForChargebacksCurrentYear
-8677000
CY2020Q4 kpti Revenue Recognition Fees Rebates And Other Incentives
RevenueRecognitionFeesRebatesAndOtherIncentives
2193000
CY2020Q4 kpti Revenue Recognition Sales Return
RevenueRecognitionSalesReturn
669000
CY2020Q4 kpti Revenue Recognition Discounts Charge Backs Fees Rebates Other Incentives And Sales Returns
RevenueRecognitionDiscountsChargeBacksFeesRebatesOtherIncentivesAndSalesReturns
4941000
CY2021 kpti Revenue Recognition Provision For Discounts And Charge Backs
RevenueRecognitionProvisionForDiscountsAndChargeBacks
13546000
CY2021 kpti Revenue Recognition Provision For Fees Rebates And Other Incentives
RevenueRecognitionProvisionForFeesRebatesAndOtherIncentives
7849000
CY2021 kpti Revenue Recognition Sale Returns Reserve For Sale Returns
RevenueRecognitionSaleReturnsReserveForSaleReturns
-235000
CY2021 kpti Revenue Recognition Provision For Discounts Charge Backs Fees Rebates Other Incentives And Sales Returns
RevenueRecognitionProvisionForDiscountsChargeBacksFeesRebatesOtherIncentivesAndSalesReturns
21160000
CY2021 kpti Revenue Recognition Payments For Chargebacks Current Year
RevenueRecognitionPaymentsForChargebacksCurrentYear
-13714000
CY2021 kpti Revenue Recognition Payments For Fees Rebates And Other Incentives Current Year
RevenueRecognitionPaymentsForFeesRebatesAndOtherIncentivesCurrentYear
-7736000
CY2021 kpti Revenue Recognition Payments For Discounts Charge Backs Fees Rebates Other Incentives And Sales Returns
RevenueRecognitionPaymentsForDiscountsChargeBacksFeesRebatesOtherIncentivesAndSalesReturns
-90000
CY2021 kpti Revenue Recognition Credits For Discounts Charge Backs Fees Rebates Other Incentives And Sales Returns Current Year
RevenueRecognitionCreditsForDiscountsChargeBacksFeesRebatesOtherIncentivesAndSalesReturnsCurrentYear
-21540000
CY2021Q4 kpti Revenue Recognition Discounts And Charge Backs
RevenueRecognitionDiscountsAndChargeBacks
1911000
CY2021Q4 kpti Revenue Recognition Fees Rebates And Other Incentives
RevenueRecognitionFeesRebatesAndOtherIncentives
2306000
CY2021Q4 kpti Revenue Recognition Sales Return
RevenueRecognitionSalesReturn
344000
CY2021Q4 kpti Revenue Recognition Discounts Charge Backs Fees Rebates Other Incentives And Sales Returns
RevenueRecognitionDiscountsChargeBacksFeesRebatesOtherIncentivesAndSalesReturns
4561000
CY2022 kpti Revenue Recognition Provision For Discounts And Charge Backs
RevenueRecognitionProvisionForDiscountsAndChargeBacks
17920000
CY2022 kpti Revenue Recognition Provision For Fees Rebates And Other Incentives
RevenueRecognitionProvisionForFeesRebatesAndOtherIncentives
9979000
CY2022 kpti Revenue Recognition Sale Returns Reserve For Sale Returns
RevenueRecognitionSaleReturnsReserveForSaleReturns
219000
CY2022 kpti Revenue Recognition Provision For Discounts Charge Backs Fees Rebates Other Incentives And Sales Returns
RevenueRecognitionProvisionForDiscountsChargeBacksFeesRebatesOtherIncentivesAndSalesReturns
28118000
CY2022 kpti Revenue Recognition Payments For Chargebacks Current Year
RevenueRecognitionPaymentsForChargebacksCurrentYear
-16966000
CY2022 kpti Revenue Recognition Payments For Fees Rebates And Other Incentives Current Year
RevenueRecognitionPaymentsForFeesRebatesAndOtherIncentivesCurrentYear
-8551000
CY2022 kpti Revenue Recognition Payments For Discounts Charge Backs Fees Rebates Other Incentives And Sales Returns
RevenueRecognitionPaymentsForDiscountsChargeBacksFeesRebatesOtherIncentivesAndSalesReturns
-21000
CY2022 kpti Revenue Recognition Credits For Discounts Charge Backs Fees Rebates Other Incentives And Sales Returns Current Year
RevenueRecognitionCreditsForDiscountsChargeBacksFeesRebatesOtherIncentivesAndSalesReturnsCurrentYear
-25538000
CY2022Q4 kpti Revenue Recognition Discounts And Charge Backs
RevenueRecognitionDiscountsAndChargeBacks
2865000
CY2022Q4 kpti Revenue Recognition Fees Rebates And Other Incentives
RevenueRecognitionFeesRebatesAndOtherIncentives
3734000
CY2022Q4 kpti Revenue Recognition Sales Return
RevenueRecognitionSalesReturn
542000
CY2022Q4 kpti Revenue Recognition Discounts Charge Backs Fees Rebates Other Incentives And Sales Returns
RevenueRecognitionDiscountsChargeBacksFeesRebatesOtherIncentivesAndSalesReturns
7141000
CY2022Q4 us-gaap Inventory Raw Materials And Supplies
InventoryRawMaterialsAndSupplies
1370000
CY2021Q4 us-gaap Inventory Raw Materials And Supplies
InventoryRawMaterialsAndSupplies
1797000
CY2022Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
1878000
CY2021Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
1895000
CY2022Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
976000
CY2021Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
414000
CY2022Q4 us-gaap Inventory Net
InventoryNet
4224000
CY2021Q4 us-gaap Inventory Net
InventoryNet
4106000
CY2020Q2 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
1300000
CY2021Q3 kpti Additional Common Share Issued On Assets Acquired
AdditionalCommonShareIssuedOnAssetsAcquired
75000
CY2022 kpti Contract With Customer License And Other Revenue
ContractWithCustomerLicenseAndOtherRevenue
36629000
CY2021 kpti Contract With Customer License And Other Revenue
ContractWithCustomerLicenseAndOtherRevenue
111383000
CY2020 kpti Contract With Customer License And Other Revenue
ContractWithCustomerLicenseAndOtherRevenue
31875000
CY2022Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
265906000
CY2022Q4 us-gaap Embedded Derivative Fair Value Of Embedded Derivative Liability
EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability
2800000
CY2022Q4 us-gaap Embedded Derivative Fair Value Of Embedded Derivative Liability
EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability
2800000
CY2021Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
95101000
CY2021Q4 us-gaap Embedded Derivative Fair Value Of Embedded Derivative Liability
EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability
3080000
CY2021Q4 us-gaap Embedded Derivative Fair Value Of Embedded Derivative Liability
EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability
3080000
CY2022Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
143123000
CY2022 us-gaap Available For Sale Debt Securities Gross Unrealized Gain
AvailableForSaleDebtSecuritiesGrossUnrealizedGain
4000
CY2022 us-gaap Available For Sale Debt Securities Gross Unrealized Loss
AvailableForSaleDebtSecuritiesGrossUnrealizedLoss
348000
CY2022Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
142779000
CY2021Q4 kpti Available For Sale Securities In Unrealized Loss Positions Qualitative Disclosure Number Of Positions Less Than One Years
AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsLessThanOneYears
10
CY2021Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
38161000
CY2021 us-gaap Available For Sale Debt Securities Gross Unrealized Gain
AvailableForSaleDebtSecuritiesGrossUnrealizedGain
4000
CY2022Q4 kpti Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax Other Than Temporary Impairments
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxOtherThanTemporaryImpairments
0
CY2021Q4 kpti Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax Other Than Temporary Impairments
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxOtherThanTemporaryImpairments
0
CY2022 kpti Debt Instrument Convertible Threshold Measurement Period Description
DebtInstrumentConvertibleThresholdMeasurementPeriodDescription
during the five-business day period immediately after any five consecutive trading day period
CY2022Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
129131000
CY2022Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
348000
CY2022 us-gaap Debt Instrument Convertible Threshold Consecutive Trading Days1
DebtInstrumentConvertibleThresholdConsecutiveTradingDays1
5
CY2022Q4 kpti Deferred Tax Assets Tax Deferred Expense Reserves And Accruals And Other Temporary Differences
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAndOtherTemporaryDifferences
6613000
CY2022Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
129131000
CY2022Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss
DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
348000
CY2021Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
26650000
CY2021Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
9000
CY2021Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
26650000
CY2021Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss
DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
9000
CY2022 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
35399000
CY2021 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
29783000
CY2020 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
24407000
CY2022 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
35399000
CY2021 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
29783000
CY2020 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
24407000
CY2022 kpti Principal Amount Of Notes Used In Conversion Rate
PrincipalAmountOfNotesUsedInConversionRate
1000
CY2022 kpti Debt Instrument Convertible Threshold Maximum Percentage Of Product Of Last Reported Sale Price Of Common Stock
DebtInstrumentConvertibleThresholdMaximumPercentageOfProductOfLastReportedSalePriceOfCommonStock
0.98
CY2021Q4 kpti Accrued Research And Development Costs Current
AccruedResearchAndDevelopmentCostsCurrent
15894000
CY2022Q4 us-gaap Interest Payable Current
InterestPayableCurrent
11673000
CY2021Q4 us-gaap Interest Payable Current
InterestPayableCurrent
21978000
CY2022 us-gaap Operating Lease Cost
OperatingLeaseCost
2800000
CY2021 us-gaap Operating Lease Cost
OperatingLeaseCost
2800000
CY2020 us-gaap Operating Lease Cost
OperatingLeaseCost
2800000
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
3718000
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
3817000
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
2918000
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
10453000
CY2022Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
1484000
CY2022Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
8969000
CY2022Q4 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P2Y9M18D
CY2022Q4 us-gaap Lessee Operating Lease Discount Rate
LesseeOperatingLeaseDiscountRate
0.11
CY2022Q4 kpti Legal Claims Outstanding
LegalClaimsOutstanding
0
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
19625000
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
19687000
CY2022Q4 kpti Accrued Research And Development Costs Current
AccruedResearchAndDevelopmentCostsCurrent
15600000
CY2022Q4 kpti Product Rebates Discounts Reserves And Royalties Current
ProductRebatesDiscountsReservesAndRoyaltiesCurrent
5110000
CY2021Q4 kpti Product Rebates Discounts Reserves And Royalties Current
ProductRebatesDiscountsReservesAndRoyaltiesCurrent
3938000
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
6407000
CY2021Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
7624000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
58415000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
69121000
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
7784000
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
7699000
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
6645000
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
6057000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1139000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1642000
CY2022 us-gaap Defined Contribution Plan Employer Matching Contribution Percent
DefinedContributionPlanEmployerMatchingContributionPercent
0.04
CY2022 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
3100000
CY2021 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
2900000
CY2020 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
2900000
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
400000
CY2021 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
300000
CY2020 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
300000
CY2022 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
0
CY2021 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
0
CY2020 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
0
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
892000
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
-30052000
CY2020 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
-37088000
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-165814000
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-93768000
CY2020 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-158876000
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-164922000
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-123820000
CY2020 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-195964000
CY2022Q4 kpti Deferred Tax Assets Operating Loss Carryforwards Domestic And State And Local
DeferredTaxAssetsOperatingLossCarryforwardsDomesticAndStateAndLocal
189629000
CY2021Q4 kpti Deferred Tax Assets Operating Loss Carryforwards Domestic And State And Local
DeferredTaxAssetsOperatingLossCarryforwardsDomesticAndStateAndLocal
187762000
CY2022Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
100436000
CY2021Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
88091000
CY2022Q4 kpti Deferred Tax Assets Fixed Assets And Intangibles
DeferredTaxAssetsFixedAssetsAndIntangibles
27312000
CY2021Q4 kpti Deferred Tax Assets Fixed Assets And Intangibles
DeferredTaxAssetsFixedAssetsAndIntangibles
28268000
CY2022Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
13818000
CY2021Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
12555000
CY2021Q4 kpti Deferred Tax Assets Tax Deferred Expense Reserves And Accruals And Other Temporary Differences
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAndOtherTemporaryDifferences
5964000
CY2022Q4 kpti Deferred Tax Assets Interest Expense
DeferredTaxAssetsInterestExpense
9236000
CY2021Q4 kpti Deferred Tax Assets Interest Expense
DeferredTaxAssetsInterestExpense
3704000
CY2022Q4 kpti Deferred Tax Assets Lease Liability
DeferredTaxAssetsLeaseLiability
2193000
CY2021Q4 kpti Deferred Tax Assets Lease Liability
DeferredTaxAssetsLeaseLiability
2676000
CY2022 kpti Effective Income Tax Rate Reconciliation At Migrated Intellectual Property Income Tax Rate Percent
EffectiveIncomeTaxRateReconciliationAtMigratedIntellectualPropertyIncomeTaxRatePercent
0
CY2021 kpti Effective Income Tax Rate Reconciliation At Migrated Intellectual Property Income Tax Rate Percent
EffectiveIncomeTaxRateReconciliationAtMigratedIntellectualPropertyIncomeTaxRatePercent
0.139
CY2020 kpti Effective Income Tax Rate Reconciliation At Migrated Intellectual Property Income Tax Rate Percent
EffectiveIncomeTaxRateReconciliationAtMigratedIntellectualPropertyIncomeTaxRatePercent
0.021
CY2022 us-gaap Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent
EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent
-0.020
CY2022Q4 kpti Deferred Tax Assets Ahydo Interest
DeferredTaxAssetsAhydoInterest
0
CY2021Q4 kpti Deferred Tax Assets Ahydo Interest
DeferredTaxAssetsAhydoInterest
2069000
CY2022Q4 us-gaap Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
27748000
CY2021Q4 us-gaap Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
388000
CY2022Q4 kpti Deferred Tax Assets Royalty Embaded Derivatives
DeferredTaxAssetsRoyaltyEmbadedDerivatives
679000
CY2021Q4 kpti Deferred Tax Assets Royalty Embaded Derivatives
DeferredTaxAssetsRoyaltyEmbadedDerivatives
720000
CY2022Q4 kpti Deferred Tax Assets Deferred Royalty Obligations
DeferredTaxAssetsDeferredRoyaltyObligations
1805000
CY2022Q4 kpti Deferred Tax Assets Unicap
DeferredTaxAssetsUnicap
1214000
CY2021Q4 kpti Deferred Tax Assets Unicap
DeferredTaxAssetsUnicap
903000
CY2022Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
379166000
CY2021Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
330902000
CY2022Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
1517000
CY2021Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
2198000
CY2022Q4 kpti Deferred Tax Liabilities Convertible Debt Amortization
DeferredTaxLiabilitiesConvertibleDebtAmortization
5000
CY2021Q4 kpti Deferred Tax Liabilities Convertible Debt Amortization
DeferredTaxLiabilitiesConvertibleDebtAmortization
6000
CY2022Q4 kpti Deferred Tax Liabilities Right Of Use Asset
DeferredTaxLiabilitiesRightOfUseAsset
1512000
CY2021Q4 kpti Deferred Tax Liabilities Right Of Use Asset
DeferredTaxLiabilitiesRightOfUseAsset
1849000
CY2022Q4 kpti Deferred Tax Liabilities Deferred Royalty Obligation
DeferredTaxLiabilitiesDeferredRoyaltyObligation
0
CY2021Q4 kpti Deferred Tax Liabilities Deferred Royalty Obligation
DeferredTaxLiabilitiesDeferredRoyaltyObligation
-343000
CY2022Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
1517000
CY2021Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
2198000
CY2022Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0
CY2021Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0
CY2022 kpti Tax Cuts And Jobs Act Capitalized Research And Development Costs
TaxCutsAndJobsActCapitalizedResearchAndDevelopmentCosts
131400000
CY2022 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
0
CY2021 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
0
CY2020 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
0
CY2022 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
48300000
CY2022 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2021 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2020 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2022 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.040
CY2021 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.008
CY2020 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.016
CY2022 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense
EffectiveIncomeTaxRateReconciliationNondeductibleExpense
-0.033
CY2021 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense
EffectiveIncomeTaxRateReconciliationNondeductibleExpense
-0.027
CY2020 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense
EffectiveIncomeTaxRateReconciliationNondeductibleExpense
-0.010
CY2022 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
0.063
CY2021 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
0.113
CY2020 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
0.065
CY2022 us-gaap Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential
EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
-0
CY2021 us-gaap Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential
EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
-0.052
CY2020 us-gaap Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential
EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
-0.041
CY2022 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.293
CY2021 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.354
CY2020 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.257
CY2021 us-gaap Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent
EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent
-0.043
CY2020 us-gaap Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent
EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent
-0.006
CY2022 us-gaap Effective Income Tax Rate Reconciliation Prior Year Income Taxes
EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes
0
CY2021 us-gaap Effective Income Tax Rate Reconciliation Prior Year Income Taxes
EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes
-0.005
CY2020 us-gaap Effective Income Tax Rate Reconciliation Prior Year Income Taxes
EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes
0.003
CY2022 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.031
CY2021 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
0.009
CY2020 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.003
CY2022 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.002
CY2021 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.002
CY2020 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.002
CY2022 kpti Fair Market Value Of The Rights Upfront Payment
FairMarketValueOfTheRightsUpfrontPayment
75000000.0
CY2022 kpti Operating Loss And Tax Credit Carryforwards Limitations Period Over Which Cumulative Changes In Ownership Interest Of Significant Shareholders Considered
OperatingLossAndTaxCreditCarryforwardsLimitationsPeriodOverWhichCumulativeChangesInOwnershipInterestOfSignificantShareholdersConsidered
P3Y
CY2022 kpti Operating Loss And Tax Credit Carryforwards Limitations Threshold Percentage Of Cumulative Changes In Ownership Interest Of Significant Shareholders Considered
OperatingLossAndTaxCreditCarryforwardsLimitationsThresholdPercentageOfCumulativeChangesInOwnershipInterestOfSignificantShareholdersConsidered
50
CY2022Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2021Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2020Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0

Files In Submission

Name View Source Status
FilingSummary.xml Edgar Link unprocessable
kpti-20221231_cal.xml Edgar Link unprocessable
0000950170-23-003129-index-headers.html Edgar Link pending
0000950170-23-003129-index.html Edgar Link pending
0000950170-23-003129.txt Edgar Link pending
0000950170-23-003129-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
img93571088_0.jpg Edgar Link pending
img93571088_1.jpg Edgar Link pending
img93571088_2.jpg Edgar Link pending
kpti-20221231.htm Edgar Link pending
kpti-20221231.xsd Edgar Link pending
kpti-ex10_14.htm Edgar Link pending
kpti-ex10_20.htm Edgar Link pending
kpti-ex10_23.htm Edgar Link pending
kpti-ex10_25.htm Edgar Link pending
kpti-ex10_29.htm Edgar Link pending
kpti-ex21_1.htm Edgar Link pending
kpti-ex23_1.htm Edgar Link pending
kpti-ex31_1.htm Edgar Link pending
kpti-ex31_2.htm Edgar Link pending
kpti-ex32_1.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
kpti-20221231_def.xml Edgar Link unprocessable
kpti-20221231_lab.xml Edgar Link unprocessable
kpti-20221231_pre.xml Edgar Link unprocessable
kpti-20221231_htm.xml Edgar Link completed
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R73.htm Edgar Link pending
R74.htm Edgar Link pending
R75.htm Edgar Link pending
R76.htm Edgar Link pending
R77.htm Edgar Link pending
R78.htm Edgar Link pending
R79.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending